Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for tse:ecg
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.95 - 1.76
Open     -
Vol / Avg. 0.00/359,178.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.11
Shares 117.36M
Beta     -
Inst. own     -
May 12, 2017
Q2 2017 Merus Labs International Inc Earnings Release (Estimated)
May 11, 2017
Q2 2017 Merus Labs International Inc Earnings Call
May 1, 2017
Merus Labs International Inc at Bloom Burton & Co. Healthcare Investor Conference
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -5.18% -10.39%
Operating margin 6.23% 0.38%
EBITD margin - 44.57%
Return on average assets -1.32% -2.96%
Return on average equity -2.51% -5.00%
Employees 13 -
CDP Score - -

Address

100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
TORONTO, ON M5K 1H1
Canada
+1-905-7260995 (Phone)
+1-416-5934434 (Fax)

Website links

Description

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.